CA9 and nonpapillary renal cell carcinoma: The phase II STARLITE 2, open-label, single-arm study will attempt to build on these results by combining nivolumab with the 177Lu-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab (177Lu-girentuximab) in patients with previously treated advanced ccRCC.